Epigral (NSE:EPIGRAL) Change In Receivables : ₹0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Epigral Change In Receivables?

Epigral's change in receivables for the quarter that ended in Mar. 2025 was ₹0 Mil. It means Epigral's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Epigral's change in receivables for the fiscal year that ended in Mar. 2025 was ₹-538 Mil. It means Epigral's Accounts Receivable increased by ₹538 Mil from Mar. 2024 to Mar. 2025 .

Epigral's Accounts Receivable for the quarter that ended in Mar. 2025 was ₹2,323 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Epigral's Days Sales Outstanding for the three months ended in Mar. 2025 was 33.78.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Epigral's liquidation value for the three months ended in Mar. 2025 was ₹-7,408 Mil.

Epigral Change In Receivables Historical Data

The historical data trend for Epigral's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigral Change In Receivables Chart

Epigral Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Change In Receivables

Get a 7-Day Free Trial

-423.40

-1,376.00

905.00

-124.70

-538.00

Epigral Quarterly Data
	Mar18	Mar19	Mar20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Epigral Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Epigral (NSE:EPIGRAL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Epigral's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2323.2	/	6276.3	*	91
=	33.78

2. In Ben Graham's calculation of liquidation value, Epigral's accounts receivable are only considered to be worth 75% of book value:

Epigral's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1388.5	-	12479.1	+	0.75 * 2323.2	+	0.5 * 3879.9
=	-7,408

Epigral Change In Receivables Related Terms

Thank you for viewing the detailed overview of Epigral's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigral Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Epigral Ltd (NSE:EPIGRAL) » Definitions » Change In Receivables

Traded in Other Exchanges

543332:India

Address

Corporate Road, 5th Floor, 6th Floor & 7th Floor, Meghmani House, Behind Safal Profitaire, Prahladnagar, Ahmedabad, GJ, IND, 380015

Website

https://www.epigral.com

Epigral Ltd is a producer of Chlor-Alkali and its Derivatives and specialty chemicals with backward and forward integration facilities. It manufactures Caustic Soda, Caustic Potash, CPVC Resin, Epichlorohydrin, Chlorine, Hydrogen, Chloromethanes, and Hydrogen Peroxide. The company is focused on servicing domestic as well as international markets.

Epigral Headlines

No Headlines